## Food and Drug Administration Center for Drug Evaluation and Research

## **Endocrinologic and Metabolic Drugs Advisory Committee**

Holiday Inn 8170 Wisconsin Avenue Bethesda, Maryland

Agenda	1	<b>January 13-15, 2003</b>		
8:00	Call to Order and Opening Remarks	Thomas Aoki, M.D.		
	Introduction of Committee	Acting Chair, EMDAC		
	Conflict of Interest Statement	Karen M. Templeton-Somers, Ph.D. Acting Executive Secretary, EMDAC		
BL 103979, Fabrazyme <sup>™</sup> (agalsidase beta), Genzyme Corporation - proposed for the treatment of Fabry's disease				
8:10	Introduction	CBER		
8:15	<b>Sponsor Presentation</b>	<b>Genzyme Corporation</b>		
9:15	Questions from the Committee			
9:45	Break			
10:00	FDA Presentation			
11:00	Questions from the Committee			
11:30	Open Public Hearing			

12:30

1:30

5:00

Lunch

Committee Discussion and Vote

Estimated Time of Adjournment

January 14, 2003		
8:00	Call to Order and Opening Remarks	Thomas Aoki, M.D. Acting Chair, EMDAC
	Introduction of Committee	
	Conflict of Interest Statement	Karen M. Templeton-Somers, Ph.D. Acting Executive Secretary, EMDAC

## BL 103977, Replagal™ (agalsidase alfa) - Transkaryotic Therapies, Inc. - proposed for the treatment of Fabry's disease

8:10	Introduction	CBER
8:15	Sponsor Presentation	Transkaryotic Therapies, Inc.
9:15	Questions from the Committee	
9:45	Break	
10:00	FDA Presentation	
11:00	Questions from the Committee	
11:30	Open Public Hearing	
12:30	Lunch	
1:30	Committee Discussion and Vote	
5:00	Estimated Time of Adjournment	

January 15, 2003		
8:00	Call to Order and Opening Remarks	Thomas Aoki, M.D. Acting Chair, EMDAC
	Introduction of Committee	
	Conflict of Interest Statement	Karen M. Templeton-Somers, Ph.D. Acting Executive Secretary, EMDAC

## BL 125058, Aldurazyme $^{\text{\tiny TM}}$ (laronidase), BioMarin Pharmaceutical Inc.

-proposed for the treatment of mucopolysaccharidosis

8:10	Introduction	CBER
8:15	<b>Sponsor Presentation</b>	BioMarin Pharmaceutical Inc.
9:15	Questions from the Committee	
9:45	Break	
10:00	FDA Presentation	
11:00	Questions from the Committee	
11:30	Open Public Hearing	
12:30	Lunch	
1:30	Committee Discussion and Vote	
5:00	Estimated Time of Adjournment	